FBXO9, F-box protein 9, 26268

N. diseases: 7; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0023893
Disease: Liver Cirrhosis, Experimental
Liver Cirrhosis, Experimental
0.300 Biomarker disease CTD_human Systems level analysis and identification of pathways and networks associated with liver fibrosis. 25380136 2014
CUI: C0023418
Disease: leukemia
leukemia
0.010 Biomarker disease BEFREE Deletion of Fbxo9 in the murine hematopoietic system showed no adverse effects on stem and progenitor cell function but in AML lead to markedly accelerated and aggressive leukemia development in mice with inv(16). 31684170 2019
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute
0.010 Biomarker disease BEFREE Deletion of Fbxo9 in the murine hematopoietic system showed no adverse effects on stem and progenitor cell function but in AML lead to markedly accelerated and aggressive leukemia development in mice with inv(16). 31684170 2019
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia
0.010 Biomarker disease BEFREE Deletion of Fbxo9 in the murine hematopoietic system showed no adverse effects on stem and progenitor cell function but in AML lead to markedly accelerated and aggressive leukemia development in mice with inv(16). 31684170 2019
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.010 Biomarker disease BEFREE Altered expression of CG5961, a putative Drosophila melanogaster homologue of FBXO9, provides a new model of Parkinson disease. 27173356 2016
CUI: C1285162
Disease: Degenerative disorder
Degenerative disorder
0.010 Biomarker group BEFREE The third gene in this family, FBXO9, is related to growth signaling, but the role of this gene in degenerative disease pathways has not been thoroughly investigated. 27173356 2016
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.010 AlteredExpression disease BEFREE Thus, mTORC1-specific degradation of the Tel2 and Tti1 proteins represents a central mTOR regulatory mechanism with implications in multiple myeloma, both in promoting survival and in providing targets for the specific treatment of multiple myeloma with high levels of Fbxo9 expression. 23263282 2013